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Abstract
Purpose Midostaurin (PKC412) is a multitargeted tyro-
sine kinase inhibitor of FMS-like tyrosine kinase 3 receptor
(FLT3), c-KIT, and other receptors. Midostaurin is active
in patients with acute myeloid leukemia and systemic
mastocytosis. Although no substantive risk for cardiac
abnormalities has been observed with midostaurin in clin-
ical studies thus far, some TKIs have been shown to affect
cardiac repolarization. Here we evaluated midostaurin’s
effect on cardiac repolarization.
Methods This phase I study evaluated the effect of
midostaurin (75 mg twice daily for 2 days; 75 mg once on
day 3) on the heart rate–corrected QT (QTc) interval in a
parallel design with active (moxiﬂoxacin) and placebo
control arms in healthy volunteers.
Results The maximum mean QTc change from base-
line corrected using Fridericia’s correction (QTcF) for
midostaurin compared with placebo was 0.7 ms at 24 h
post dose on day 3. The highest upper bound of the 1-sided
95% CI was 4.7 ms, which excluded 10 ms, demonstrating
a lack of QTcF prolongation effect. Assay sensitivity was
demonstrated by modeling the moxiﬂoxacin plasma con-
centration versus QTcF change from baseline, which
showed a clear positive increase in QTcF with increasing
moxiﬂoxacin plasma concentrations, as expected based on
previous studies. In the 4-day evaluation period, a minority
of participants (34.6%) experienced an adverse event;
97.0% were grade 1. No grade 3 or 4 adverse events were
reported.
Conclusion Midostaurin demonstrated a good safety
proﬁle in healthy volunteers, with no prolonged cardiac
repolarization or other changes on the electrocardiogram.
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Introduction
Midostaurin (PKC412; N-benzoylstaurosporin) is a multi-
targeted tyrosine kinase inhibitor (TKI) of several class III
receptor tyrosine kinases with known roles in hematopoi-
esis and leukemia. These receptors include wild-type and
mutant variants of the FMS-like tyrosine kinase 3 receptor
(FLT3), c-KIT, platelet-derived growth factor receptor-b,
and others [1]. Mutations leading to constitutive activation
of FLT3, which is involved in regulating the proliferation,
differentiation, and apoptosis of myeloid progenitors, occur
in the blasts of about 30% of patients with acute myeloid
leukemia (AML) [2–4], highlighting the potential utility of
therapies targeting FLT3 in AML treatment. Furthermore,
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selectivity suggests that less-selective FLT3 inhibitors or
those with broader tyrosine kinase inhibition proﬁles may
offer a cytotoxic advantage in patients with newly diag-
nosed AML [5].
Midostaurin has demonstrated activity as a single agent
[6], has induced complete remissions in combination with
chemotherapy in patients with AML [7], and is currently
under evaluation in a phase III registration trial in patients
with newly diagnosed FLT3-mutant AML at a dose of
50 mg twice daily in combination with standard chemo-
therapy [8].
The inhibitory activity of midostaurin against c-KIT is
also of interest because of the role that mutations in
c-KIT play in aggressive systemic mastocytosis (ASM).
Mutations in c-KIT are found in approximately 80% of
patients with ASM [9]. Preliminary results of a multi-
center, phase II study of midostaurin (100 mg twice
daily) in 26 patients with ASM, mast cell leukemia, or
systemic mastocytosis without an associated hematologic
clonal nonmast cell lineage disease (AHNMD) demon-
strated that patients achieved a high overall response rate
of 69%, regardless of c-KIT mutation status [10]. A
global phase II study was initiated to evaluate the efﬁ-
cacy and safety of midostaurin (100 mg twice daily until
progressive disease, intolerability, or withdrawal) in
patients with ASM or mast cell leukemia with or without
an AHNMD [11].
The plasma concentrations of midostaurin and its
metaboliteCGP62221accumulateinatime-linearmannerin
the ﬁrst 3–5 days of daily oral dosing [12]. Thereafter, the
pharmacokinetics (PK) become nonlinear, with a large
increaseinbioavailabilitybetweenday5andday28toreach
a new ‘‘pseudo steady state.’’ In contrast, the longer-lasting
hydroxymetabolite CGP52421 continues to accumulate to
reach approximately seven times the concentration of
midostaurinandCGP62221atsteadystate.Biliaryexcretion
is the major pathway for elimination of midostaurin,
CGP62221, and CGP52421.
Some TKIs have been shown to affect cardiac repo-
larization, as detected by heart rate–corrected QT (QTc)
prolongation [13–18]. Although no previous clinical
studies have suggested a substantive risk for cardiac
abnormalities with midostaurin, a dedicated study has not
been conducted to investigate the possible effects of
midostaurin on the QTc corrected using Fridericia’s
correction (QTcF) interval. Described here are the results
from a randomized study using placebo and active con-
trol arms to determine whether midostaurin administered
at a dose of 75 mg twice daily for 2 days and 75 mg
once daily for 1 day affects QTcF intervals in healthy
adult volunteers.
Methods
Patients
Inclusion criteria for healthy volunteers, aged 18–45 years,
included no clinically signiﬁcant deviations from normal in
medical history, physical examination, vital signs, or
clinical laboratory determinations. A body weight between
50 and 100 kg and a body mass index between 18 and
33 kg/m
2 were also required. Exclusion criteria included,
but were not limited to, a history or family history of long
QT-interval syndrome, heart disease, and any other severe
or uncontrolled medical or psychiatric condition. Smoking
and drug and/or alcohol abuse within 30 days of random-
ization, use of prescription drugs within 14 days of ran-
domization, and use of CYP3A4 enzyme-inducing or
enzyme-inhibiting agents within 4 weeks of dosing were
prohibited. Participants were discontinued if they had
abnormal electrocardiogram (ECG) results on day -1,
during placebo run-in, and were followed until resolution
of abnormality. These participants were replaced, as is
standard in QTc studies, to ensure that a sufﬁcient number
of participants were evaluable for the ECG analysis.
Participants randomized into 1 of the 3 arms of the study
were evaluated as the randomized set, regardless of whe-
ther they ever received study medication. The safety pop-
ulation consisted of all participants who received at least 1
dose of study medication. The PK set consisted of all
participants who completed at least 1 dose of midostaurin
or moxiﬂoxacin and had evaluable PK proﬁles on day 1
and/or day 3. The ECG set consisted of participants who
completed all scheduled doses of study medication from
day 1 to day 3 and had an available baseline ECG mea-
surement and at least 1 ECG measurement on day 3.
Study design
This study was a phase I, randomized, double-blind,
placebo- and active-controlled, 3-way, parallel-group
study conducted at a single center in the United States
and approved by the Arkansas Research Medical Testing,
LLC, Institutional Review Board. The design followed the
recommendations of the International Conference on
Harmonisation of Technical Requirements for Registra-
tion of Pharmaceuticals for Human Use (ICH) E14
guideline on ‘‘The Clinical Evaluation of QT/QTc Interval
Prolongation and Proarrhythmic Potential for Non-Anti-
arrhythmic Drugs’’ [19]. As such, the trial included a
concurrent positive control group and addressed intrinsic
variability by conducting multiple ECGs at baseline and
during the study. The study was conducted according to
the ethical principles of the Declaration of Helsinki, and
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123written informed consent was obtained from each subject
during screening.
Participants were randomized to 1 of 3 treatment arms:
midostaurin administered orally at 75 mg twice daily on
days 1 and 2 and a single dose on day 3, moxiﬂoxacin
administered orally at a single 400-mg dose on day 3, or
placebo (Fig. 1). The treatment regimen was selected to
achieve maximal plasma exposure for QTc evaluation
while minimizing the risks of excessive or prolonged
exposure in healthy volunteers. In a prior study, patients
with diabetes mellitus treated with multiple oral doses of
midostaurin for 28 days at 4 dose levels (25 mg twice
daily, 50 mg twice daily, 75 mg twice daily, and 75 mg 3
times daily) as well as a single oral 100-mg dose, dem-
onstrated a marked increase in frequency of adverse events
at doses above the 75-mg twice-daily dose [20]. Thus, the
75-mg twice-daily dose was expected to be safe and
effective and was associated with a midostaurin cumulative
Cmax similar to that observed with a 50-mg twice-daily
dose of midostaurin in a phase Ib study of patients with
newly diagnosed AML treated with various doses of
midostaurin [7].
Moxiﬂoxacin (400 mg) was used in the active control
arm because this agent is known to prolong QTc intervals
in a dose-dependent manner [21]. The difference in QTcF
interval prolongation between the moxiﬂoxacin and pla-
cebo arms served as an indicator of assay sensitivity.
Moxiﬂoxacin was overencapsulated to make the capsules
visually identical to the placebo. Novartis supplied cap-
sules for blinding of the active control via overencapsula-
tion by the pharmacy of the site. Dissolution testing was
performed on moxiﬂoxacin overencapsulated tablets, and
they were determined to have equivalent dissolution to
regular moxiﬂoxacin.
Because the metabolite CGP52421 exhibits a very long
half-life (up to 1 month) in human participants, a parallel
study design was used instead of a crossover design to
avoid the potential carryover effect of this analyte. This
study did not evaluate the effect of CGP52421, which
would require 21–28 days of treatment to reach the steady
state, because of ethical and safety concerns related to
long-term exposure to a drug in healthy volunteers. Study
drugs were administered at 8:00 AM and 8:00 PM;
breakfast and dinner were provided at 10:00 AM and 5:30
PM, respectively.
The primary objective of this study was to determine the
effect of multiple doses of midostaurin on the QTcF
interval. The primary variable evaluated was the change
from baseline (day -1) in the QTcF interval over the
protocol-deﬁned time points on day 3 with midostaurin.
The baseline comparison was from day -1 to day 3 at
matched time points. The secondary objectives were safety,
tolerability, cardiac intervals (QT, QTcB [corrected using
Bazett’s correction], QTcI [individually corrected], length
of QRS complex of waves, interval between RR waves
[RR], interval between PR waves [PR]), and heart rate
following multiple doses of midostaurin.
Statistical methods
To claim a lack of effect of multiple doses of midostaurin
on QTcF interval, the following hypothesis was tested
predose (0 h) and at all 8 post dose time points on day 3:
H0 : UflmidoðtÞ   lplaceboðtÞg 10;t
¼ 0;0:5;1;2;3;4;8;12; and 24 hours versus
H1 : \flmidoðtÞ   lplaceboðtÞg\10;t
¼ 0; 0:5;1;2;3;4;8;12; and 24 hours
where lmido(t) and lplacebo(t) are the mean QTcF changes
from baseline observed following all scheduled doses of
midostaurin and placebo, respectively, at time point t on
day 3. The lack of QT effect for midostaurin was estab-
lished if the null hypothesis was rejected. The null
hypothesis was rejected if the highest upper bound of the
95% 1-sided conﬁdence interval (CI) for the time-matched
mean effect (adjusted for baseline and placebo) of midos-
taurin on the QTcF interval at all time points excluded
10 ms.
The following hypothesis was tested to conﬁrm that the
study had sufﬁcient assay sensitivity:
H0 : \flmoxiðtÞ   lplaceboðtÞg 5;t
¼ 0:5;1;2;3; and 4 hours versus
H1 : UflmoxiðtÞ   lplaceboðtÞg [5;t
¼ 0:5;1;2;3; and4hours
where lmoxi(t) was the mean QTcF change from baseline
observed following moxiﬂoxacin 400 mg at time point t.I f
the null hypothesis was rejected, the study had sufﬁcient
Midostaurin
Midostaurin 25 mg Moxifloxacin 400 mg
Placebo Placebo
Arm Time
AM
PM
AM
PM
AM
PM
Baseline Day 1 Day 2 Day 3
Moxifloxacin
Placebo
Fig. 1 Study drug administration per treatment arm
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123sensitivity. The Simes method was used for the protection
of an experiment-wise 5% type I error [22, 23]. With the
Simes method, the original P values corresponding to 0.5,
1, 2, 3, and 4 h post baseline are ordered increasingly, that
is, P1 B P2 B P3 B P4 B P5. After the Simes correction,
the P values were 5P1,5 P2/2, 5P3/3, 5P4/4, and P5
respectively. If any of the 5 adjusted P values were\.05,
assay sensitivity was claimed. Only the participants who
completed all scheduled doses of study medication from
day 1 to day 3 and had at least 1 ECG on day -1 (baseline)
and at least 1 ECG on day 3 (time-matched day 3 data for
the time-matched analysis) were included in the assay
sensitivity test.
Electrocardiogram measurements at each time point
were calculated as an average of 3 separate ECG extrac-
tions or replicates. (Each extraction was the mean of 3
beats.) If fewer than 3 measurements were available, the
available samples were averaged (i.e., a minimum of 1
measure was required). For each subject, the time-matched
baseline value was subtracted from the QT/QTc intervals to
determine the change from baseline in QT/QTc intervals
for that subject. The 2 null hypotheses described above
were tested in a linear mixed-effect model with a com-
pound symmetry covariance structure. The model included
the baseline measure as covariate and treatment, time, and
the treatment-by-time interaction as ﬁxed effects, where
time was a categorical variable and subject was a random
effect.
The time-matched analysis was conducted on the QTcF
change from the time-matched baseline as recommended
by the ICH E14 guideline [19]. Although modeling change
from the time-matched baseline was the primary analysis,
the change from the time-averaged baseline was also ana-
lyzed using the same model. For the averaged baseline,
each triplicate ECG collection was averaged ﬁrst, and then
the averaged baseline was calculated based on all the
averaged triplicate ECG and unscheduled ECGs.
Exploratory analyses were performed to characterize the
relationship between drug concentrations and changes in
QT intervals to assist with interpretation of the study
results. A linear random-effects model was ﬁt to the QTcF/
QTcB/QTcI/QT change from day -1 (baseline) to day 3
and concentration data for midostaurin or its 2 metabolites
(CGP52421 and CGP62221) or moxiﬂoxacin. Baseline
QTcF was included in the model as a covariate. The QTcF
effect and its upper 1-sided 95% CI were computed at the
25% quartile, mean, 75% quartile, and median of the Cmax
for midostaurin or its 2 metabolites or moxiﬂoxacin. This
exploratory analysis was applied to both the change from
the time-matched baseline and the change from time-
averaged baseline.
Outlier analysis for QTc was also exploratory because
this study was not powered to detect individuals with
genetic sensitivity to potential QT-prolonging drugs. The
nonspeciﬁc outlier criterion was a change from baseline in
QTc interval of 30–60 ms.
Clinical assessments
Standard triplicate 12-lead ECGs were obtained at 9 time
points over 24 h at baseline on day 3 and at 2 time points
on day 1. Electrocardiogram analysis was performed at a
blinded central reading facility (ERT, East Bridgewater,
NJ) in digital format, with paper tracings obtained and
archived immediately on site. Vital signs were assessed
daily. Clinical laboratory parameters were assessed at
baseline and at the end of study. Self-reported adverse
events were continuously recorded from the ﬁrst study
treatment (placebo, day -1) through the end of study on
day 4.
Pharmacokinetic and pharmacodynamic assessments
Blood samples for PK analysis were collected predose and
0.5, 1, 2, 3, 4, 8, 12, and 24 h post dose on days 1 and 3 at
the same time as ECG assessments. Moxiﬂoxacin, midos-
taurin, CGP62221, and CGP52421 concentrations were
determined by high-performance liquid chromatography/
mass spectrometry with a limit of quantiﬁcation of 50 and
10 ng/mL respectively. Noncompartmental analysis (Win-
Nonlin
TM version 5.2, Pharsight, Sunnyvale, California)
was performed to determine the following PK parameters:
Cmax, Tmax, minimum (trough) plasma concentration over a
dosing interval (Cmin), and AUC calculated using a trape-
zoidal method. For moxiﬂoxacin, the AUC from time 0 to
the last measurable concentration sampling time was cal-
culated (AUC0–tlast). For midostaurin and its metabolites,
the AUC from time 0 to 12 h (AUC0–12h) was calculated
following the ﬁrst dose on day 1, and the AUC from 0 to
24 h (AUC0–24h) was calculated on day 3. The relationship
between drug concentration and change in QT interval was
explored to assist with interpretation of the results.
Results
Demographic parameters were well-distributed among the
study arms (Supplementary Table 1). A total of 192 heal-
thy volunteers completed the study, and 161 were consid-
ered eligible for analysis of the primary endpoint (ECG set;
n = 54 in the midostaurin arm, 64 in the placebo arm, and
43 in the moxiﬂoxacin arm). In the midostaurin arm, 24
participants discontinued the study (Table 1): 19 because
of adverse events, predominantly gastrointestinal events of
vomiting (n = 17) and 2 events of grade 1 tachycardia
during the placebo run-in period (i.e., before active
1258 Cancer Chemother Pharmacol (2012) 69:1255–1263
123treatment). All instances of vomiting occurred within 4 h
of dosing, and patients who experienced vomiting within
4 h of dosing were ineligible for the ECG set. Because data
from patients who vomited could not be used for the pri-
mary objective, these patients were discontinued immedi-
ately from the trial. No participants in the other treatment
groups discontinued because of adverse events. Sixteen
replacement participants were also enrolled to ensure that a
sufﬁcient number of participants were evaluable for the
ECG analysis.
ECG analysis
For the midostaurin treatment arm, the upper bounds of the
1-sided 95% CI for the estimated QTcF change from time-
matched baseline (compared with placebo; delta–delta
analysis) for all 9 time points on day 3 compared with
placebo were\10 ms (Fig. 2). The maximum mean change
from baseline for midostaurin compared with placebo
occurred 24 h post dose on day 3 and was 0.7 ms; its
highest upper bound of the 1-sided 95% CI was 4.7 ms,
which excluded 10 ms (Supplementary Table 2). Thus,
midostaurin did not demonstrate the potential for proar-
rhythmic effects associated with QT interval prolongation.
Consistent with time-matched analysis, the QTcF
change from time-averaged baseline demonstrated a lack of
effect on QTc prolongation. The maximum mean change
from baseline for midostaurin compared with placebo was
2.5 ms and occurred 24 h post dose on day 3. The highest
upper bound of its 95% CI was 4.9 ms. A negative or
nonsigniﬁcant concentration versus QTcF slope was
observed for midostaurin (Fig. 3a), CGP62221, and
CGP52421 concentrations (-2.3, -3.3, and 0.2, respec-
tively), conﬁrming no QT prolongation at the administered
dose.
The active control moxiﬂoxacin had a maximum mean
QTcF prolongation from time-matched baseline compared
with placebo of 10.7 ms, which occurred 1 h post dose on
day 3 (Fig. 2). The lower bound of the 1-sided 95% CI of
6.4 ms exceeded 5 ms (original P = .015), demonstrating
QT prolongation for moxiﬂoxacin. However, when the
correction of Simes was applied to adjust for multiple
comparisons, there were no statistically signiﬁcant changes
in QTcF interval from baseline at the 5 time points
(P = 0.07 at 1 h post dose). At 0.5, 2, 3, and 8 h, moxi-
ﬂoxacin had a maximum mean QTcF prolongation from
time-matched baseline of between 5 and 10 ms, with the
upper limit of the 95% CI between 10 and 15 ms (14.9 ms
at 1 h post dose).
Using time-averaged baseline, the maximum mean
change from baseline for the moxiﬂoxacin arm compared
with placebo occurred 1 h post dose on day 3 and was
10.2 ms. The lower bound of its 95% CI was 7.6 ms
(P = 0.003 at 1 h post dose, adjusted for multiple com-
parisons). Unlike with midostaurin and its metabolites,
there was a clear positive slope of QT change from baseline
with increasing plasma moxiﬂoxacin concentrations (4.0
for QT, 2.6 for QTcB, 3.2 for QTcF) that was statistically
signiﬁcant (Fig. 3b).
QTcB changes in the 30- to 60-ms category were
detected in 1 (1.3%) subject in the midostaurin arm, 7
(15.9%) participants in the moxiﬂoxacin arm, and 1 (1.5%)
subject in the placebo arm in the exploratory outlier
Table 1 Subject disposition (Randomized set)
Midostaurin
(n = 80)
Moxiﬂoxacin
(n = 44)
Placebo
(n = 68)
Participants, no. (%)
Completed 56 (70.0) 44 (100.0) 66 (97.1)
ECG set 54 (67.5) 43 (97.7) 64 (94.1)
Discontinued 24 (30.0) 0 (0.0) 2 (2.9)
Main cause of discontinuation
Death 0 (0.0) 0 (0.0) 0 (0.0)
Adverse event(s) 19 (23.8) 0 (0.0) 0 (0.0)
Abnormal test procedure 2 (2.5) 0 (0.0) 0 (0.0)
Withdrew consent 2 (2.5) 0 (0.0) 1 (1.5)
Protocol violation(s) 1 (1.3) 0 (0.0) 0 (0.0)
Administrative reasons 0 (0.0) 0 (0.0) 1 (1.5)
ECG, electrocardiogram
Moxifloxacin – Placebo
Midostaurin – Placebo
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Fig. 2 Estimated mean change (95% 1-sided CI boundaries indicated
by bars) from time-matched baseline in heart rate–corrected QT
intervals using Fridericia’s correction (QTcF) on day 3 compared with
placebo (electrocardiogram data set). QTcF, heart rate–corrected QT
interval corrected using Fridericia’s correction
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123analyses (Table 2). QTcB results between 450 and 480 ms
post baseline were also detected in 1 (1.3%) subject in the
midostaurin arm and in 1 (2.3%) subject in the moxiﬂox-
acin arm. No subject had a QTc duration [480 ms or a
change from baseline in QTc [60 ms. QRS, RR, and PR
abnormalities were uncommon in all arms (Table 2).
No symptomatic, new post baseline morphologic
waveform changes on the 12-lead ECG were identiﬁed in
the study. Three participants in the midostaurin arm had
new post baseline T-wave abnormalities at a single time
point or as a single occurrence, but these abnormalities
were deemed by the investigator not to be clinically sig-
niﬁcant. However, 1 and 4 participants in the placebo and
moxiﬂoxacin arms, respectively, experienced new post
baseline T-wave abnormalities, some at multiple time
points. No new U-wave abnormalities were noted in the
placebo or midostaurin arm, but 1 case was identiﬁed in the
moxiﬂoxacin arm.
Pharmacokinetics
Peak concentrations ofmidostaurin (SupplementaryTable 3)
were observed mainly at 1 h post dose on both days 1 and 3
(Fig. 4) and of CGP62221 and CGP52421 at 3–4 h post
dose. The mean Cmax for moxiﬂoxacin was 2544.2 ng/mL
(standard deviation [SD] = 495.0) and occurred at a median
of 2.1 h (range, 0.6–4.1 h) after administration (Supplemen-
tary Table 4). The mean AUC0–tlast of moxiﬂoxacin was 29
407.9 ng*h/mL (SD = 5165.6 ng*h/mL).
Safety
In total, 66 (34.6%) participants experienced adverse
events on the study drug (Supplementary Table 5). These
adverse events were generally mild and transient, with no
grade 3 or 4 events reported. Of the total adverse events
reported, 97.0% were grade 1. Four grade 2 events were
reported: headache (1 participant), nausea (2 participants, 1
of whom discontinued because of vomiting), and diarrhea
(1 participant). Gastrointestinal adverse events were more
common in the midostaurin arm, as expected for this
population and drug class. Two participants in the midos-
taurin arm experienced grade 1 tachycardia during the
placebo run-in period (day -1) and were discontinued
prior to treatment with midostaurin. They were both fol-
lowed until resolution of symptoms. No other cardiac
events were reported in any participants. All incidences of
vomiting occurred within 4 h of midostaurin dosing, and
these patients were not included in the ECG or PK data
analysis. There were no clinically relevant changes or
adverse events related to laboratory values or vital signs in
any treatment group.
Discussion
Because some TKIs exert unexpected pharmacologic
effects on cardiac repolarization, the current thorough QT/
QTc study was designed to assess the cardiac interval
effects of midostaurin in healthy participants. In particular,
FLT3 is recognized as a major target in the treatment of
AML, and agents speciﬁcally designed to target this
receptor, including AC220 [16] and MLN518 [17], have
been shown to induce prolongation of the QT interval in
clinical trials, as has the multikinase inhibitor sorafenib
[18].
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Fig. 3 Plasma concentrations of midostaurin (a) and moxiﬂoxacin
(b) versus change from time-matched baseline in heart rate–corrected
QT intervals using Fridericia’s correction (QTcF) on day 3 (electro-
cardiogram data set). The line represents the ﬁxed effect of the ﬁtted
concentration–QTcF model. CI, conﬁdence interval; Cmax, maximum
plasma concentration; QTcF, heart rate–corrected QT interval
corrected using Fridericia’s correction
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123In this study, we demonstrated that midostaurin, an
inhibitor of FLT3, c-KIT, and other tyrosine kinases with
established efﬁcacy in patients with AML [6, 7] and ASM
[10, 24], was not associated with prolonged cardiac repo-
larization or its related proarrhythmic effects. In a time-
matched analysis for QTcF, midostaurin had no or minimal
effect on the QT interval, with an upper bound of the 95%
CI for QTcF values corrected for both baseline and placebo
\5 ms. The threshold level of regulatory concern, as
established in the ICH E14 guideline [19], is a 10-ms mean
increase in QTc as the upper bound of the 95% CI. The
results for the time-averaged analysis were consistent with
those determined using the time-matched analysis.
Despite historical reliance on the QTc change from
baseline for determining a drug’s proarrhythmic risk, the
importance of the concentration–QT relationship in inter-
preting thorough QT studies is increasingly being realized
[25, 26]. Concentration–QTcF slopes for midostaurin and
its metabolites CGP62221 and CPG52421 were either
negative or not statistically signiﬁcant, which further sup-
ports the lack of prolonged cardiac repolarization with
midostaurin. Furthermore, the placebo arm’s mean QTcF
change from baseline was within 5 ms, demonstrating that
spontaneous factors were very well controlled.
On the basis of previous studies, the expected effect of
the active control moxiﬂoxacin on the QTcF interval was
8–13 ms [27]. Our results were consistent with this ﬁnding,
with the lower CI [5 ms at hour 1 post administration,
QTcF increases between 5 and 10 ms at 0.5, 2, 3, and 8 h
post administration, and upper CIs between 10 and 15 ms
with moxiﬂoxacin treatment. In the time-matched analysis,
these increases were not signiﬁcantly different from
placebo after multiple time point correction methods to
establish the sensitivity of the assay. In a time-averaged
analysis, however, the maximum mean change from
baseline in the moxiﬂoxacin arm compared with the pla-
cebo arm was signiﬁcant. The lack of signiﬁcance in the
time-matched analysis may be related to the slightly lower
moxiﬂoxacin Cmax observed in this study (2544 ng/mL)
compared with what has been previously reported
(2830 ng/mL) [28]. The PK proﬁle of moxiﬂoxacin was
somewhat ﬂattened, which was most likely due to over-
encapsulation [29].
Linear regression analyses showed a statistically sig-
niﬁcant positive slope of QT change from baseline with
increasing moxiﬂoxacin plasma concentrations. The
moxiﬂoxacin slope for QTcF (3.2 ms per lg/mL) was
consistent with those found in 5 other thorough QTc
studies, in which the mean slope estimates were 2.5, 2.4,
3.3, 3.5, and 4.3 ms per lg/mL [25, 26]. This positive
slope, and the fact that moxiﬂoxacin concentrations
reached levels expected for overencapsulation [29], estab-
lished the sensitivity of the assay. These ﬁndings support
the value of determining the slope of the QT-concentration
curve when overencapsulation is used for a double-blinded
positive control.
Electrocardiogram analysis demonstrated that midos-
taurin had no effects on heart rate, atrioventricular con-
duction, or cardiac depolarization, as measured by the PR
and QRS interval durations. No participants in any group
met the speciﬁc outlier criteria for U-wave or QTc interval,
although the analysis was exploratory. No QTcF, QTcB, or
QTcI changes from baseline [60 ms or results [480 ms
were detected in any arm. Overall, these data indicate that
Table 2 Participants with
notable QTc intervals and other
electrocardiogram parameters
(Safety set)
QTcF, heart rate–corrected QT
interval (QTc) corrected using
Fridericia’s correction; QTcB,
QTc corrected using Bazett’s
correction; QTcI, QTc
individually corrected; QRS,
length of QRS complex of
waves; RR, interval between RR
waves; PR, interval between PR
waves
a Time-matched change from
baseline
b Number of post baseline
values[450 ms/number of
baseline values[450 ms
Midostaurin
(n = 79)
Moxiﬂoxacin
(n = 44)
Placebo
(n = 68)
QTcF, no. (%)
[30 ms
a 00 0
[60 ms
a 00 0
New[450 ms
b 0 2/44 (4.5) 0
QTcB, no. (%)
[30 ms
a 1 (1.3) 7 (15.9) 1 (1.5)
[60 ms
a 00 0
New[450 ms
b 1/78 (1.3) 1/44 (2.3) 0
QTcI, no. (%)
[30 ms
a 00 0
[60 ms
a 00 0
New[450 ms
b 1/79 (1.3) 2/44 (4.5) 0
QRS increase C25% and resultant QRS[100 ms 0 0 0
RR increase C25% and resultant RR[1,200 ms 1 (1.3) 0 1 (1.5)
RR decrease C25% and resultant RR\600 ms 1 (1.3) 0 0
PR increase C25% and resultant PR[200 ms 0 0 0
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123no clinically relevant changes in ECG parameters were
detected in the midostaurin arm.
The adverse events experienced in this trial were mainly
mild (97% were grade 1), and the gastrointestinal events in
the midostaurin arm were expected and occurred at a lower
frequency than has been observed previously in patients
with AML treated with midostaurin [6]. Overall, midos-
taurin at a dose of 75 mg twice daily was safe and gener-
ally well tolerated in these healthy participants in a 4-day
evaluation period.
The results of the concentration–QTcF regression anal-
ysis showed no evidence that midostaurin or its metabolite
CGP62221 affected QTc duration, whereas the positive
control moxiﬂoxacin demonstrated the expected relation-
ship between its concentration and the change in QTc.
Despite the lack of prolonged cardiac repolarization with
midostaurin in this carefully conducted study, we recom-
mend continued ECG monitoring in clinical trials, but at a
reduced frequency, as the QT effects of the long-lasting
metabolite CGP52421 were not fully addressed in this
relatively short study with a 4-day evaluation period.
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